Moleculin Biotech, Inc. (MBRX): Price and Financial Metrics


Moleculin Biotech, Inc. (MBRX): $1.27

-0.02 (-1.55%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MBRX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MBRX Stock Price Chart Interactive Chart >

Price chart for MBRX

MBRX Price/Volume Stats

Current price $1.27 52-week high $2.05
Prev. close $1.29 52-week low $0.82
Day low $1.24 Volume 21,300
Day high $1.32 Avg. volume 51,111
50-day MA $1.26 Dividend yield N/A
200-day MA $1.38 Market Cap 36.36M

Moleculin Biotech, Inc. (MBRX) Company Bio


Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company was founded in 2015 and is based in Houston, Texas.


MBRX Latest News Stream


Event/Time News Detail
Loading, please wait...

MBRX Latest Social Stream


Loading social stream, please wait...

View Full MBRX Social Stream

Latest MBRX News From Around the Web

Below are the latest news stories about MOLECULIN BIOTECH INC that investors may wish to consider to help them evaluate MBRX as an investment opportunity.

JTC Team to Host the Virtual Investor 2023 Companies to Watch Event on January 17th, 18th, and 19th

JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today announced it will host the Virtual Investor 2023 Companies to Watch Event, January 17-19, 2023.

Yahoo | January 11, 2023

Moleculin to Present at the Virtual Investor 2023 Companies to Watch Event

Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that Walter Klemp, President and Chief Executive Officer of Moleculin, will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 9:00 AM ET.

Yahoo | January 5, 2023

Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced it has received approval from the Agenzia Italiana del Farmaco (AIFA, the Italian Medicines Agency competent authority) and the Istituto Superiore di Sanità (ISS, the Italian National Institute of Health) for its Phase 1/2 trial evaluating Annamycin in combination with Cytarabine (Ara-C

Yahoo | December 21, 2022

Is Moleculin Biotech (NASDAQ:MBRX) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Yahoo | December 19, 2022

Moleculin Biotech's Annamycin In Leukemia Study Shows 80% Overall Response Rate

Moleculin Biotech Inc (NASDAQ: MBRX) provided an update on its clinical programs evaluating Annamycin for relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases. The data exhibited an 80% overall response rate (ORR) in the final cohort (n=5) of the European trial of Annamycin as a single agent with one CRi (complete response with incomplete recovery of peripheral blood count) and three PRs (Partial Response). Of 42 subjects in three of the company's Ann

Yahoo | December 15, 2022

Read More 'MBRX' Stories Here

MBRX Price Returns

1-mo 12.39%
3-mo 28.32%
6-mo -23.95%
1-year -9.93%
3-year -75.50%
5-year -89.47%
YTD 19.81%
2022 -43.01%
2021 -61.11%
2020 -12.89%
2019 -12.01%
2018 -44.09%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6478 seconds.